Get Aleteia delivered to your inbox. Subscribe here
Start your mornings with the good, the beautiful, the true... Subscribe to Aleteia's free newsletter!
Sign me up!

Not Prepared to Donate?

Here are 5 ways you can still help Aleteia:

  1. Pray for our team and the success of our mission
  2. Talk about Aleteia in your parish
  3. Share Aleteia content with friends and family
  4. Turn off your ad blockers when you visit
  5. Subscribe to our free newsletter and read us daily
Thank you!
Team Aleteia



Hope: Newly engineered antibody targets 99 percent of HIV strains


The “tri-specific antibody” attacks the virus in 3 different areas.

A collaboration between the US National Institute of Health and the pharmaceutical company Sanofi has resulted in the creation of a new antibody, which targets 99 oercent of HIV strains. The antibody was built to attack three crucial parts of the virus, making it harder for the virus to evolve and lowering its resistance.

The greatest challenge researchers face in determining the best strategy to fight HIV is the virus’ propensity to shift and evolve — to change its appearance, creating various strains. BBC reminds us that the variant strains of HIV in a single infected patient can be equivalent to the number of strains of influenza during a worldwide flu season.

Breakthroughs came about after a small group of patients developed “broadly neutralizing antibodies,” sometimes called “super-antibodies.” Researchers use these to treat and prevent infection.

BBC reports that the study, published in the journal Science, involved combining three such antibodies into a “tri-specific antibody” that Dr. Gary Nabel, Chief Scientific Officer at Sanofi, claims has “greater breadth than any single naturally occurring antibody that has been discovered.”

So far, the research team is in the animal testing phase of development. Experiments on 24 monkeys have revealed that those exposed to the “tri-specific antibodies” did not become infected when later injected with HIV. Human trials are expected to begin some time in 2018.

Director of the US National Institute of Allergy and Infectious Diseases Dr. Anthony Fauci was intrigued by the approach, saying, “Combinations of antibodies that each bind to a distinct site on HIV may best overcome the defenses of the virus in the effort to achieve effective antibody-based treatment and prevention.”

Get Aleteia delivered to your inbox. Subscribe here.
Aleteia offers you this space to comment on articles. This space should always reflect Aleteia values.
[See Comment Policy]
Readers like you contribute to Aleteia's Mission.

Since our inception in 2012, Aleteia’s readership has grown rapidly worldwide. Our team is committed to a mission of providing articles that enrich, inspire and inform a Catholic life. That's why we want our articles to be freely accessible to everyone, but we need your help to do that. Quality journalism has a cost (more than selling ads on Aleteia can cover). That's why readers like you make a major difference by donating as little as $3 a month.